Cablivi 10 mg Caplacizumab

Cablivi 10mg (caplacizumab) is approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP) and is available in powder form or solution for injection for use in conjunction with plasma exchange and immunosuppressive therapy. The drug used in acquired thrombotic thrombocytopenic purpura (aTTP) disease indications is produced by Ablynx NV. Approved by the European Medicine Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Cablivi 10mg is administered intravenously, that is, by administering the drug directly into the vein.

Cablivi 10 mg Caplacizumab​ You can contact us to find out the price:

Contact for detailed information Prospectus
Important Notice: We do not have any activities such as drug sales, drug supply or drug promotion on our site. In addition, there is no help or counseling service on medical matters on our site. All information on the site has been prepared for patients and doctors to have information about drugs. Our site is not under legal responsibility for the incomplete or not updated information on our site. Our users entering the site are deemed to have accepted these conditions. Please consult your doctor before using medication.
Related Keywords

Contact Now

You can contact us immediately to get information about our products and services, and to get answers to your questions.

Contact Now